Ramsey Hachem
University of Utah · University of Utah Medical Center · Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ramsey Hachem as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:50 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06990711 · A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung TransplantationWashington University School of Medicine · recruiting · Antibody Mediated Rejection of Lung Transplant · principal investigator
- Ph2NCT06033196 · Tocilizumab in Lung TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Lung Transplant · study chair
- Ph1/Ph2NCT02351180 · Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant RecipientsWashington University School of Medicine · completed · Lung Transplant Infection · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung TransplantationR33HL169189 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2025 to 2026 · $596,825 awarded in 2026Same name and institution; not confirmed by an ID
- Incorporating Donor Lung CT Images into Machine Learning Models to Predict Severe Primary Graft Dysfunction after Lung TransplantationR01HL177046 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2025 to 2026 · $758,611 awarded in 2026Same name and institution; not confirmed by an ID
- Multidisciplinary Pulmonary and Critical Care Training ProgramT32HL105321 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2025 to 2026 · $397,398 awarded in 2026Same name and institution; not confirmed by an ID
- Phase 1 clinical trial of complement inhibition in primary graft dysfunction after lung transplantationR61HL187358 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2026 · $397,615 awarded in 2026Same name and institution; not confirmed by an ID
- A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung TransplantationR61HL169189 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2023 to 2024 · $283,671 awarded in 2024Grant number is on one of their registry trials
- A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression in Lung TransplantationR34HL138186 · NHLBI · WASHINGTON UNIVERSITY · fiscal years 2018 to 2020 · $237,979 awarded in 2020Same name and institution; not confirmed by an ID
- TREATMENT OF ANTI-HLA ANTIBODIES TO PREVENT BOS AFTER LUNG TRANSPLANTATIONR34HL105412 · NHLBI · WASHINGTON UNIVERSITY · fiscal years 2010 to 2011 · $691,367 awarded in 2011Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:50 UTC. The ranking covers the 200 most relevant of 33 PubMed records, and a shared surname and initials can bring in a namesake. All 33 on PubMed
- Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.Clin Infect Dis · 2007553 citationsRCR 19.0
- A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group.N Engl J Med · 1999540 citationsRCR 21.0
- 455 citationsRCR 19.7
- Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.Clin Infect Dis · 2005246 citationsRCR 7.1
- Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.Antimicrob Agents Chemother · 2006218 citationsRCR 7.7
- Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.Clin Infect Dis · 2006217 citationsRCR 7.7
- Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation.J Heart Lung Transplant · 2010188 citationsRCR 6.2
- A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation.J Heart Lung Transplant · 2007120 citationsRCR 3.8
- Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin.Crit Care Med · 199875 citationsRCR 3.2
- Minocycline-ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer.Clin Infect Dis · 200369 citationsRCR 2.2